This prompted the evaluation of MTL-CEBPA combined with the multi-kinase inhibitor sorafenib in a randomized phase II trial in patients with hepatocellular carcinoma (NCT04710641). The gene discussed is CEBPA; the disease is hepatocellular carcinoma.